Associations of Serum 25-Hydroxyvitamin D Concentrations with Risks of Mortality and Cardiovascular Disease among Individuals with Psoriasis - Supplementary Material

Associations of Serum 25-Hydroxyvitamin D Concentrations with Risks of Mortality and Cardiovascular Disease among Individuals with Psoriasis.

Supplemental Data
eTables
eTable 1. Identification of Psoriasis Based on the Hospital Inpatient Care Records, Primary Care Records, and Self-Reported Data in the UK Biobank
eTable 2. Identification of Cardiovascular Diseases Based on the Hospital Inpatient Care Records, Primary Care Records, and Self-Reported Data in the UK Biobank at baseline
eTable 3. Mean Concentrations of Serum 25-Hydroxyvitamin D by Month of Blood Draw among Psoriasis Patients in terms of Overall Mortality
eTable 4. Ascertainment of Incident Cardiovascular Diseases During Follow-up Based on the Hospital Inpatient Care Records, Primary Care Records, Self-Reported Medical Condition and National Death Register in the UK Biobank
eTable 5. Associations of Serum 25-Hydroxyvitamin D Concentrations with Risks of Overall Mortality and Incident Cardiovascular Disease among Patients with Psoriasis
eTable 6. Stratified Analyses on the Associations between Serum 25-Hydroxyvitamin D Concentrations and Risk of Overall Mortality and Incident Cardiovascular Disease among Patients with Psoriasis
eTable 7. Sensitivity Analyses on the Associations of Serum 25-Hydroxyvitamin D Concentrations with Risks of Overall Mortality and Incident Cardiovascular Disease among Patients with Psoriasis
eTable 8. Associations of Serum 25-Hydroxyvitamin D Concentrations with Risks of Overall Mortality and Incident Cardiovascular Disease among Patients with Psoriasis after Further Adjustment for Kidney Function and Serum Calcium Concentrations
eTable 9. Baseline Characteristics of Participants without Psoriasis According to Level of Serum 25-Hydroxyvitamin D in the UK Biobank in terms of Overall Mortality
eTable 10. Multivariable-Adjusted HRs and 95% CIs for Risk of Overall Mortality or Incident CVD Comparing Psoriasis Patients to Matched Controls

eFigures
eFigure 1. Flowchart of the Study Design in the Analyses of Psoriasis Patients alone in the UK Biobank
eFigure 2. Flowchart of the Study Design for the Comparison between Psoriasis Patients and their Individually Matched Controls in terms of Overall Mortality in the UK Biobank
eFigure 3. Flowchart of the Study Design for the Comparison between Psoriasis Patients and their Individually Matched Controls in terms of Cardiovascular Disease Incidence in the UK Biobank
eFigure 4. Associations of Serum 25-Hydroxyvitamin D Concentrations with Risks of Overall Mortality and Incident Cardiovascular Disease among Psoriasis Patients and their Individually Matched Controls

Supplemental eMethods
Supplemental eResults